Osteoporosis Treatment Market - Global Industry Insights, Trends, Outlook, and Opportunity Analysis, 2022 - 2028

Osteoporosis Treatment Market - Global Industry Insights, Trends, Outlook, and Opportunity Analysis, 2022 - 2028

Osteoporosis is a bone related disease that weakens bones and increase the risk of fracture and breaking of bones. The factors responsible for osteoporosis include, long-term use of high-dose oral corticosteroids, a family history of osteoporosis – particularly history of a hip fracture in a parent, having a low body mass index (BMI), heavy drinking and smoking, and others. The prevalence of osteoporosis is high among the adult population. For instance, according to a report by National Osteoporosis Foundation in 2016, around 54 million adult in the U.S were suffering from osteoporosis or have low bone density.
Market Dynamics
Increasing approvals and launches of novel osteoporosis drugs is expected to significantly drive the osteoporosis treatment market growth over forecast period. For instance, in 2013, Pfizer Inc. received the U.S. Food and Drug Administration (FDA) approval for its drug— DUAVEETM (conjugated estrogens/bazedoxifene) 0.45mg / 20mg tablets—for the treatment of moderate-to-severe vasomotor symptoms associated with menopause and the prevention of postmenopausal osteoporosis. Furthermore, osteoporosis commonly affects older adults and increasing geriatric population is expected to lead to high demand for osteoporosis treatment drugs. For instance, according to a report by United Nations Population Fund, people aged 60 years and above accounted for 12.3% of the global population in 2015 and this is expected to reach 22% by 2050 that accounts for 2 billion people.
Key features of the study:

This report provides in-depth analysis of the osteoporosis treatment market and provides market size (US$ Billion) and Compound Annual Growth Rate (CAGR %) for the forecast period (2022-2028), considering 2021 as the base year
It elucidates potential revenue opportunity across different segments and explains attractive investment proposition matrix for this market
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, regional outlook, and competitive strategy adopted by leading players
It profiles leading players in the global osteoporosis treatment market based on the following parameters – company overview, financial performance, product portfolio, geographical presence, distribution strategies, key developments, and strategies, and future plans
Key companies covered as a part of this study include, EffRx Pharmaceuticals SA, Daiichi Sankyo Company, Limited, Amgen Inc., Dr Reddy\'s Laboratories, Mylan Inc., Pfenex Inc., Eli Lilly and Company, Asahi Kasei Corporation, F.Hoffmann La Roche, Teva Pharmaceutical Industries Ltd., Novartis AG, Merck & Co AG, GlaxoSmithKline Plc., Allergan plc., and Pfizer Inc.
Insights from this report would allow marketers and the management authorities of the companies to make informed decision regarding their future product launches, technological up-gradation, market expansion, and marketing tactics
The global osteoporosis treatment market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
Stakeholders would have ease in decision-making through the various strategy matrices used in analyzing the osteoporosis treatment market

Detailed Segmentation:

Global Osteoporosis Treatment Market, by Drug Type :

Bisphosphonates

Alendronate
Risedronate
Ibandronate
Zoledronic Acid
Others

Calcitonin
Hormone Therapy
Selective Estrogen Receptor Modulators (SERMs)
Parathyroid Hormone-Related Protein (PTHrP) Analog
Rank Ligand (RANKL) Inhibitor

Global Osteoporosis Treatment Market, by Route of Administration:

Oral
Injectable
Others

Global Osteoporosis Treatment Market, by Distribution Channel:

Hospitals
Online Pharmacies
Retail Pharmacies

Global Osteoporosis Treatment Market, by Geography:

North America

Drug Type:

Bisphosphonates

Alendronate
Risedronate
Ibandronate
Zoledronic Acid
Others

Calcitonin
Hormone Therapy
Selective Estrogen Receptor Modulators (SERMs)
Parathyroid Hormone-Related Protein (PTHrP) Analog
Rank Ligand (RANKL) Inhibitor

By Route of Administration:

Oral
Injectable
Others

By Distribution Channel

Hospitals
Online Pharmacies
Retail Pharmacies

By Country:

U.S.
Canada

Europe

Drug Type:

Bisphosphonates

Alendronate
Risedronate
Ibandronate
Zoledronic Acid
Others

Calcitonin
Hormone Therapy
Selective Estrogen Receptor Modulators (SERMs)
Parathyroid Hormone-Related Protein (PTHrP) Analog
Rank Ligand (RANKL) Inhibitor

By Route of Administration:

Oral
Injectable
Others

By Distribution Channel

Hospitals
Online Pharmacies
Retail Pharmacies

By Country:

U.K.
Germany
Italy
France
Spain
Russia
Rest of Europe

Asia Pacific

Bisphosphonates

Alendronate
Risedronate
Ibandronate
Zoledronic Acid
Others

Calcitonin
Hormone Therapy
Selective Estrogen Receptor Modulators (SERMs)
Parathyroid Hormone-Related Protein (PTHrP) Analog
Rank Ligand (RANKL) Inhibitor

By Route of Administration:

Oral
Injectable
Others

By Distribution Channel

Hospitals
Online Pharmacies
Retail Pharmacies

By Country:

China
India
Japan
ASEAN
Australia
South Korea
Rest of Asia Pacific

Latin America

Drug Type:

Bisphosphonates

Alendronate
Risedronate
Ibandronate
Zoledronic Acid
Others

Calcitonin
Hormone Therapy
Selective Estrogen Receptor Modulators (SERMs)
Parathyroid Hormone-Related Protein (PTHrP) Analog
Rank Ligand (RANKL) Inhibitor

By Route of Administration:

Oral
Injectable
Others

By Distribution Channel

Hospitals
Online Pharmacies
Retail Pharmacies

By Country:

Brazil
Mexico
Argentina
Rest of Latin America

Middle East

Drug Type:

Bisphosphonates

Alendronate
Risedronate
Ibandronate
Zoledronic Acid
Others

Calcitonin
Hormone Therapy
Selective Estrogen Receptor Modulators (SERMs)
Parathyroid Hormone-Related Protein (PTHrP) Analog
Rank Ligand (RANKL) Inhibitor

By Route of Administration:

Oral
Injectable
Others

By Distribution Channel

Hospitals
Online Pharmacies
Retail Pharmacies

By Country:

GCC
Israel
Rest of Middle East

Africa

Drug Type:

Bisphosphonates

Alendronate
Risedronate
Ibandronate
Zoledronic Acid
Others

Calcitonin
Hormone Therapy
Selective Estrogen Receptor Modulators (SERMs)
Parathyroid Hormone-Related Protein (PTHrP) Analog
Rank Ligand (RANKL) Inhibitor

By Route of Administration:

Oral
Injectable
Others

By Distribution Channel

Hospitals
Online Pharmacies
Retail Pharmacies

By Country:

Central Africa
South Africa
North Africa

Company Profiles

Teva Pharmaceutical Industries Ltd.*

Company Overview
Product Portfolio
Financial Performance
Key Strategies
Recent Developments

Daiichi Sankyo Company Limited.
Amgen Inc.
Dr Reddy\'s Laboratories
Mylan Inc.
Pfenex Inc.
Eli Lilly and Company
Asahi Kasei Corporation
F.Hoffmann La Roche
EffRx Pharmaceuticals SA
Novartis AG
Merck & Co AG
GlaxoSmithKline Plc.
Allergan plc.
Pfizer Inc.

“*” marked represents similar segmentation in other categories in the respective section.